ANCER™ - THE "ANSWER" TO CANCER
Superior Neo-Epitope Selection Powered by Advanced In-Silico Machine-Learning Algorithms
Traditional Neo-Epitope selection methods are cumbersome, non-validated and generate Neo-Epitopes that are mostly non-immunogenic or that can potentially trigger either an immune suppressive response or an adverse immune related adverse event.
EpiVax Oncology's Ancer™ neoantigen in silico prediction platform, leverages EpiVax's EpiMatrix® and JanusMatrix™ algorithms, state-of-the-art tools that have been externally validated in several prospective vaccine studies and that are broadly utilized worldwide by pharmaceutical and biotechnology companies. Ancer™ is designed to enable the discovery of highly immunogenic neoantigens for precision cancer immunotherapies. It is integrated into an end-to-end, GMP ready, robust and already established commercial-grade platform.
In addition, Ancer™ (via JanusMatrix™) enables the rapid, in silico, discovery and removal of both:
The "Self-Like" inhibitory Treg neoepitopes that may trigger an immune suppressive response.
The “Self-Like” cross-reactive neoepitopes that may trigger an immune related adverse event.